Skip to main content
Premium Trial:

Request an Annual Quote

Sophia Genetics Gets CE-IVD Mark for Cancer Detection Solution

NEW YORK (GenomeWeb) – Sophia Genetics said today that it has received CE-IVD designation for its Solid Tumor Solution (STS) molecular diagnostic application.

Sophia STS was designed to detect and characterize genomic alterations in 42 clinically relevant genes related to various solid tumors across multiple types of cancer, the Lausanne, Switzerland-based company said. The application runs on top of the Sophia AI artificial intelligence platform.

According to Sophia, STS can detect single-nucleotide variants, insertions and deletions, and gene amplification events. It also can identify microsatellite instability status in six loci associated with colorectal cancer.

"It is designed to maximize diagnostic yield and guide treatment and management decisions," Gioia Althoff, senior vice president for genomics at Sophia Genetics, said in a statement.

Jose López, head of the molecular biology laboratory at the Instituto Valenciano de Oncología in Valencia, Spain, added that STS has helped the cancer center streamline its genomic testing workflow.

"With the STS, our lab has access to a comprehensive solution that accurately detects clinically relevant genomic alterations associated with solid tumors, accelerating the clinicians’ ability to diagnose patients and deliver the best treatment options," he said.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.